NEW YORK (GenomeWeb News) – MDxHealth and Plus Diagnostics today announced a co-promotional deal covering MDxHealth's epigenetic test for prostate cancer in the US.

Plus Diagnostics will build awareness for MDx Health's ConfirmMDx test through its national network of urologists. Financial and other terms of the deal were not disclosed.

"The national reach afforded by Plus Diagnostics provides a direct channel to the urology community and will aid in meeting the growing demand for our test," MDxHealth CEO Jan Groen said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.